Hims & Hers stock slips premarket after FDA “illegal copycat drugs” warning clouds $49 Wegovy-style pill
Shares of Hims & Hers Health dipped 3.8% to $23.48 in premarket trading Friday, following a tough day on Thursday.
Hims & Hers (HIMS) stock whipsaws on $49 Wegovy copycat pill as legal, FDA risks sharpen
Hims & Hers Health shares ended Thursday at $23.48, slipping 3.8% after volatile trading tied to its shift toward a cheaper, compounded form of Novo Nordisk’s new Wegovy pill.
Hims & Hers stock whipsaws on $49 Wegovy-copy pill as legal threats cloud next move
Shares of Hims & Hers Health dropped 3.2% to $23.63 Thursday afternoon, as the telehealth company expanded into the weight-loss drug market by launching a $49 compounded version of Novo Nordisk’s new Wegovy pill. The stock fluctuated between $22.98 and $29.44 on heavy volume.
Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus
Shares of Hims & Hers Health Inc fell 0.5% to $32.87 in premarket trading on Wednesday after closing down 3.1% at $33.04 in the prior session. The stock has traded between $23.97 and $72.98 over the past 52 weeks. Google
Hims & Hers stock slides into year-end as investors weigh Ohio buildout and macro calendar
Hims & Hers Health Inc shares last closed down about 1% at $34.31 on Friday, extending a four-session slide as U.S. markets headed into the final trading days of the year. Investing.com
Hims Stock (HIMS) Outlook for 2026: Latest News, Canada Expansion, Buyback and Price Targets as of December 6, 2025
Meta description: Hims & Hers Health is back in the spotlight after a new $250 million buyback, expansion into Canada, and fresh acquisitions in lab testing and blood diagnostics. Here’s a comprehensive look at HIMS stock price, latest news, GLP‑1 risks, and Wall Street forecasts as of December 6, 2025.
Hims & Hers Health (HIMS) Stock Today: Canada Expansion, Labs, GLP‑1 Growth and Fresh “Strong Buy” Call – Price, News & Forecast as of December 5, 2025
Hims & Hers Health, Inc. is back in the market spotlight. As of early December 5, 2025, the telehealth company’s stock is trading around $40 per share, up sharply from recent lows but still far below its 52‑week high near $73.StockAnalysis
Hims & Hers (HIMS) Stock Jumps on Canada Launch and YourBio Deal: Latest News, Forecasts and Analysis for December 4, 2025
Hims & Hers Health, Inc. is back in the spotlight. In Thursday’s session on December 4, 2025, the telehealth stock climbed roughly 5–8%, trading around $40 and valuing the company at about $12.8 billion, after a flurry of strategic announcements. Finviz+1
Hims & Hers Health (HIMS) Stock Jumps on Policy Tailwinds and Buyback Momentum — November 24, 2025
Below is a news-style, SEO-optimized breakdown of Hims & Hers Health stock today, the fresh catalysts moving the share price, and the key fundamentals and risks investors are watching.
Hims & Hers Health (HIMS) Stock Today, November 23, 2025: Price, Buyback and GLP‑1 Risks
After Friday’s session, HIMS closed at $34.71, up about 3.2% on the day. That puts the stock roughly 43–44% higher year‑to‑date, yet still almost 50% below its 2025 peak near $73.StockAnalysis+2PortfoliosLab+2
HIMS Stock Today (November 18, 2025): Buyback, GLP‑1 Price War and What It Means for Hims & Hers Investors
On Tuesday, November 18, 2025, Hims & Hers Health is trading in the shadow of a sharp sell‑off, a fresh $250 million share repurchase authorization, and escalating price competition in the weight‑loss drug market. Together, these forces are shaping how traders and long‑term investors are thinking about HIMS stock today.
Hims & Hers Health (HIMS) Stock Falls as New ‘Labs’ Platform With Quest Diagnostics Launches – November 14, 2025 Update
Hims & Hers Health, Inc. is in the spotlight today after officially rolling out its new “Labs” diagnostic platform in partnership with Quest Diagnostics, even as the stock trades sharply lower and Wall Street sentiment turns more cautious. The telehealth company is trying to push deeper into preventive, data-led healthcare at the same time investors are digesting rich valuations, insider selling and tighter 2025 guidance. Investing.com+4Hims Investors+4Investing.com Australia+4
Hims & Hers (HIMS) Stock Soars on Subscriber Surge and GLP-1 Deal Buzz – Nov 2025 Update
Hims & Hers Health’s stock closed on Nov 3, 2025 at $44.39, down about 2.3% for the daystockanalysis.com. This modest dip came amid a broader mixed market and ahead of the company’s earnings release after the bell. However, immediately following its Q3 earnings report that evening, HIMS shares jumped roughly 6% in after-hours trading, climbing to around $46.70investing.com. The post-market pop was driven by upbeat revenue and subscriber numbers, signaling renewed investor optimism.
Palantir’s ‘Otherworldly’ Earnings & Wegovy Deal Buzz Spark After-Hours Stock Fireworks
Palantir Technologies delivered a record third quarter, easily topping analyst expectations on both revenue and profit. The company’s revenue jumped 63% year-over-year to $1.18 billion, with adjusted earnings of $0.21 per share – well above estimates of about $0.17investopedia.com. CEO Alex Karp credited booming demand for Palantir’s Artificial Intelligence Platform, especially among commercial customers. U.S. commercial revenue more than doubled to $397 million, outpacing even robust growth in government contractsinvestopedia.com. Karp hailed the commercial business as an “absolute juggernaut” and lauded the company’s “otherworldly” AI-driven growth in a letter to investorsinvestopedia.com.
Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React
Analyst outlook & forecast: Long-term, analysts model robust growth. For example, one financial model projects ~18% revenue CAGR: ~$3.3 billion in sales by 2028 and ~$261 million net incomesimplywall.st. Another estimate sees revenue rising from ~$2.35 B in 2025 to ~$3.34 B by 2027tipranks.com, and free cash flow turning positive in 2025simplywall.st. These forecasts assume continued momentum in weight-loss/metabolic services plus gains in new verticals. Yet many investors note the high valuation and regulatory/legal risks. Community “fair value” estimates vary widely due to uncertaintysimplywall.st. Key analysts maintain Holds in light of decelerating growth and competition, though they acknowledge solid subscription volumes and expanding offeringstipranks.com.
Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom
Hims & Hers’ expansion into menopause care was greeted with enthusiasm in the market. On October 15, the San Francisco–based telehealth provider announced it is now offering affordable treatment plans for women in perimenopause and menopause via its Hers platform businesswire.com businesswire.com. The move adds a new specialty to Hers, which already serves over 500,000 women subscribers businesswire.com. By connecting patients with providers trained in menopause care, Hims & Hers aims to fill a long-neglected gap in women’s health. “Women have been navigating an outdated healthcare system that wasn’t designed for them for too long. Hers was built to serve every woman on her terms,” said Dr. Jessica Shepherd, Chief Medical Officer of Hims & Hers businesswire.com businesswire.com. She noted that the goal is “building a platform that women can trust to access the care they need,” by increasing access to specialists for every life stage businesswire.com.
Menopause Launch Sends Hims & Hers (HIMS) Stock Soaring – What’s Next?
On Oct. 15, Hims & Hers stunned the market by launching a dedicated menopause/perimenopause care program on its “Hers” telehealth platform. The company said the new service would connect women with personalized hormone therapies to ease symptoms like hot flashes and sleep issuests2.tech. This push into a historically underserved sector met eager investor demand. As Benzinga and TS2.tech reported, HIMS stock raced +10–13% that day, trading near $60 with extremely heavy volumets2.tech. By the close, HIMS was up roughly +16%, a one-day gain not seen in monthsts2.techts2.tech.
Hims & Hers Stock Soars on New Menopause Care Expansion – What Comes Next?
Hims & Hers’ women’s health platform now offers specialized menopause and perimenopause careinvestors.hims.com. The new service is aimed at improving access to hormone therapies for symptoms like hot flashes and sleep issues, expanding a platform that already serves over 500,000 women.
Digital Health & Telemedicine Industry Update (June–July 2025)
The summer of 2025 brought a surge of activity in digital health and telemedicine. Major telehealth providers announced mergers and strategic shifts, new virtual care platforms launched, and governments advanced telehealth-friendly policies. Below is a comprehensive roundup of key developments, market trends, regulatory updates, and tech advancements shaping the digital health sector in June and July 2025.